A carregar cotações...
Previsão
Não temos dados de analistas para esta empresa.
Discussões na comunidade
Ainda não há nenhuma discussão sobre este ativo.
Iniciar discussãoNotícias Ir para o feed de notícias
Incannex Healthcare reports quarterly loss per share of $0.15
Incannex Healthcare reported earnings per share of -$0.15 for the quarter ended June 30, 2026, presented at the finance conference on September 25, 2026. For the fiscal year it reported a loss per share of -$1.66, after -$40.50 in the prior year. » Mais em finanzen.net
Incannex Healthcare receives AUD 6.04m tax credit and expects a further AUD 5.1m
Incannex Healthcare has received a payment of AUD 6,039,162.43 from the Australian research and development incentive program and expects additional tax credits of AUD 5.1 million in 2026. The expected total proceeds from this non-dilutive capital therefore exceed AUD 11.1 million. The funds are intended to support further development of clinical programs such as IHL-42X and PSX-001 and capital allocation measures, including a share buyback program. » Mais em de.investing.com
Incannex starts DReAMzz study to optimise dosing of IHL-42X for obstructive sleep apnea
Incannex has begun the clinical DReAMzz crossover study to optimise dosing of IHL-42X (dronabinol/acetazolamide) for the treatment of obstructive sleep apnea. The company lists 14 identified study centres, completed manufacturing of the investigational products, and secured import/export approvals and distribution agreements to activate the sites. IHL-42X has Fast Track status with the FDA; Incannex notes rapid cash burn despite positive balance-sheet metrics and says adequate funding is critical (market capitalization: $53.8m; share price: $3.90). » Mais em de.investing.com
Incannex reactivates stock buyback program after pause
Incannex resumed its stock buyback program after a period of inactivity over the last two trading days and says it will opportunistically continue repurchasing shares. The biopharmaceutical company reports about $75 million in cash following a financing round, is debt-free and shows a very high short-term liquidity ratio (Current Ratio 48.27). The stock trades at $3.41, below the InvestingPro fair value of $4.06; as of 31.12.2025 roughly $18.5 million remained available for buybacks. Incannex stresses the decision reflects a discrepancy between market valuation and its financial position as well as progress in the clinical pipeline (including IHL-42X, PSX-001). » Mais em de.investing.com
Incannex has about $75m in cash after financing round and is debt-free
Incannex has roughly $75 million in cash following a financing round led by institutional healthcare investors and carries no debt. Market capitalization is around $46 million, which together with the liquidity position results in a negative enterprise value. The proceeds are intended primarily to fund the phase‑2 dosing‑optimization study DReAMzz for IHL‑42X (obstructive sleep apnea); IHL‑42X has FDA Fast Track status. The company plans dose administrations in the coming months, has an approved share buyback program, and is concurrently advancing development of PSX‑001 (oral synthetic psilocybin). » Mais em de.investing.com
Dados financeiros da empresa
| (EUR) | 2023 | YoY |
|---|---|---|
| Receitas | 618,83 mil | 20,15% |
| Ganho bruto | 618,83 mil | 21,13% |
| Ganho líquido | -12,19 mi | 122,65% |
| EBITDA | -10,79 mi | 361,24% |
Dados fundamentais
| Métrica | Valor |
|---|---|
Capitalização bolsista | € 8,73 mi |
Número de ações | 347,71 mi |
Máximo/mínimo de 52 semanas | € 0,17 - € 0,0251 |
| Dividendos | Não |
Beta | 2,09 |
PER (PE Ratio) | -2,88 |
PEG (PEG Ratio) | -0,03 |
P/VC (PB Ratio) | 0,37 |
P/V (PS Ratio) | 0,00 |
Perfil da empresa
A Incannex Healthcare Limited dedica-se à investigação, desenvolvimento e venda de produtos canabinoides medicinais na Austrália. Oferece produtos canabinoides de qualidade farmacêutica sob a marca Incannex. Os produtos da empresa incluem o IHL-42X, que se encontra em ensaios clínicos de Fase II para a apneia obstrutiva do sono; o IHL-216A para lesão cerebral traumática; e o IHL-675A, uma combinação de hidroxicloroquina e canabidiol para a prevenção e tratamento de doenças inflamatórias pulmonares, como a síndrome do desconforto respiratório agudo, a doença pulmonar obstrutiva crónica, a asma e a bronquite, bem como a artrite reumatoide e as doenças inflamatórias intestinais. A empresa tem parcerias com o The Alfred Hospital e a Novotech no programa clínico do IHL-42X para a apneia obstrutiva do sono; e com o Monash Trauma Group do Departamento de Neurociência da Universidade de Monash para realizar um estudo sobre o efeito protetor do IHL-216A em concussões desportivas. A empresa era anteriormente conhecida como Impression Healthcare Limited e mudou o nome para Incannex Healthcare Limited em junho de 2020. A Incannex Healthcare Limited foi constituída em 2001 e tem sede em Sydney, Austrália.
| Nome | INCANNEX HEALTHCARE LTD. |
| CEO | Joel Bradley Latham |
| Sede | Sydney,
nsw Austrália |
| Site | |
| Entrada em bolsa | 23/05/2007 |
| Colaboradores | 3 |
Símbolos de ticker
| Bolsa | Símbolo |
|---|---|
Australian Securities Exchange Ltd | IHL.AX |